ASCO 2015: ( DCTH ) Delcath Systems Shows Life-Extending Results Treating Liver Cancer Patients
By The ASCO Post
Posted: 5/31/2015 7:50:52 PM
Clinicians continue to produce positive, life-extending results treating liver cancer patients with CHEMOSAT in multiple tumor types
CHEMOSAT is well tolerated and is an easy-to-learn procedure for an experienced treatment team
Multiple treatment courses of at least four procedures have been shown to be safe and well tolerated while continuing to provide clinical benefit and good quality of life
6 Key Cancer Winners From ASCO Presentations
By Chris Lange June 1, 2015 9:40 am EDT
Vascular Biogenics Ltd. (NASDAQ: VBLT) announced interim results for its ongoing Phase 2 study of VB-111 in patients with recurring glioblastoma. Overall, the data presented showed a statistically significant overall survival benefit. Shares of Vascular Biogenics closed Friday up 9.1% at $8.05 to close outfor a strong week. In early trading, shares rose 5% to $8.45. The stock has a consensus analyst price target of $13.00.
Adam Feuerstein @adamfeuerstein 23m23 minutes ago
$PBYI up to 17% of women taking neratinib still have grade 3 diarrhea despite huge doses of Imodium. Bet they feel great! #ASCO15
Big Pharmas Eyeing ESPR, Founder Recreated Lipitor & Made Them Billions.
he's on to the next multibagger.
that is correct View Filing in HTMLView Filing in RTFView Filing in PDFView Filing in ExcelView Filing in Original FormatView Filing in XBRL F-1 05/29/15
CyberArk Files For Secondary Offering After Strong Q1
BY GILLIAN RICH, INVESTOR'S BUSINESS DAILY
6-8-15 08:54 AM ET
CyberArk Software (NASDAQ:CYBR) said Friday it filed for a follow-on stock offering.
The cybersecurity company filed a registration statement with the Securities and Exchange Commission for the secondary offering. The majority of the shares will be sold by current shareholders with $50 million in shares to be sold by CyberArk. The total number of shares to be sold hasn't been decided yet.
Nice uote From MD Anderson President
MD Anderson President Ron DePinho, M.D., said:
Genetically engineering our patients’ immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting approaches with curative potential in oncology today. We believe coupling MD Anderson’s unique CAR T cell approach with the powerful technologies of ZIOPHARM and Intrexon will allow us to build T cells that hit cancer harder, with greater precision, under tighter control and with potentially fewer side effects for patients. This agreement ranks as one of MD Anderson’s most substantial collaborations and will provide significant resources to fuel its mission of Making Cancer History
want to be in for that !